Skip to main Content

Trump blasts drugmakers and middlemen for high U.S. drug prices

  • Author: Yasmeen Abutaleb, Reuters
  • Updated: May 11
  • Published May 11

Health and Human Services Secretary Alex Azar listens Friday as President Donald Trump delivers a speech about lowering prescription drug prices from the Rose Garden at the White House. REUTERS/Jonathan Ernst

WASHINGTON – President Donald Trump on Friday blasted drugmakers and health care "middlemen" for making prescription drugs unaffordable for Americans, but health care stocks rose as experts said the administration avoided taking aggressive and direct measures to cut drug prices.

Trump said his administration would take aim at the "middlemen" in the drug industry who became "very very rich," an apparent reference to health insurers and pharmacy benefit managers. He also said the pharmaceutical industry is making an "absolute fortune" at the expense of American taxpayers.

"Everyone involved in the broken system – the drugmakers, insurance companies, distributors, pharmacy benefit managers, and many others — contribute to the problem," Trump said.

Trump also placed blame on foreign governments, which negotiate lower drug prices than in the U.S., saying they "extort" unreasonably low prices from U.S. drugmakers.

Trump was speaking as his health deputies released a series of proposals to address high drug costs.

The Department of Health and Human Services released what it called a blueprint titled "American Patients First" with details of its plan. It said the administration's immediate actions would include allowing commercial plans that administer Medicare Part D prescription drug benefits for seniors more power to negotiate prices with drugmakers.

The U.S. Food and Drug Administration would evaluate requiring drugmakers to include the list prices they set on medicines in their advertising. Drugmakers argue that list prices do not reflect actual cost with discounts and rebates.

Some of the administration's longer-term priorities include restricting use of rebates, creating incentives for drugmakers to lower list prices in Medicare, and investigating tools to address foreign government practices that it said could be harming innovation and driving up U.S. prices.

Health care experts said Trump's plan sounded like rhetoric rather than substantive change for an industry where prices rise substantially more than inflation each year.

"There's not a big proposal here that is going to make a huge difference. There are a bunch of smaller technical changes," said Sam Richardson, Associate Professor of Economics at Boston College.

Regarding forcing other countries to pay more for drugs, Richardson said: "We don't really have the policy levers to get that to happen."

Health and Human Services Secretary Alex Azar said during a White House briefing that many of the actions the government was considering would not require the U.S. Congress, but could take place through executive action within months. He said it would take years to restructure the U.S. drug system.

(Additional reporting by Caroline Humer, Lewis Krauskopf and Michael Erman)

Local news matters.

Support independent, local journalism in Alaska.